Medical Policy and Coding Updates - July 2023
Summary
Effective September 1, 2023, Premera HMO added Zilretta (triamcinolone acetonide extended-release injectable suspension) as medically necessary for moderate to severe osteoarthritis pain of the knee in adults, approved once per knee per lifetime, and considers it investigational for all other indications. Effective August 4, 2023, Xgeva (denosumab) was added for the prevention of skeletal-related events in individuals with bone metastases from solid tumors and in individuals with multiple myeloma. Effective July 1, 2023, Premera HMO added medical necessity criteria for Veozah and Elfabrio, expanded Sotyktu trial and failure criteria to three of the listed agents, and made maternal serum biomarker tests for preeclampsia or spontaneous preterm birth investigational.
Get alerts when payers change rules like this one
We check Premera Blue Cross and other payers every day and email you when a change matches your specialty and state.